drugset / Trial / NCT00199862
Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer
Completed
30 enrolled
Memorial Sloan Kettering Cancer Center
Ludwig Institute for Cancer Research · collab
NaSingle-groupOpen-labelDiagnostic
Summary
The purpose of this study is to determine whether our drug, 124I-huA33, can safely detect colorectal cancer.
Timeline
- Start
- 2004-02
- Primary completion
- 2025-07-02
- Completion
- 2025-07-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | huA33 | Monoclonal antibody | 10 mg | Intravenous |